{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:18:13Z","timestamp":1772810293242,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.4065\/81.9.1177","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:27:47Z","timestamp":1232760467000},"page":"1177-1185","source":"Crossref","is-referenced-by-count":28,"title":["Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial"],"prefix":"10.4065","volume":"81","author":[{"given":"Thomas A.","family":"Pearson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margo A.","family":"Denke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick E.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy P.","family":"Battisti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell A.","family":"Gazzara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/81.9.1177_bib1","author":"American Heart Association, American Stroke Association"},{"key":"10.4065\/81.9.1177_bib2","first-page":"121","article-title":"Disparities in premature deaths from heart disease: 50 states and the District of Columbia, 2001","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4065\/81.9.1177_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0002-8703(82)90021-7","article-title":"Coronary heart disease in black populations, I: mortality and morbidity","volume":"104","author":"Gillum","year":"1982","journal-title":"Am Heart J"},{"key":"10.4065\/81.9.1177_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-127-2-199707150-00003","article-title":"Coronary heart disease incidence and survival in African-American women and men: the NHANES I Epidemiologic Follow-up Study","volume":"127","author":"Gillum","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.9.1177_bib5","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/01.CIR.95.6.1433","article-title":"Greater incidence of hospitalized myocardial infarction among Mexican Americans than non-Hispanic whites: the Corpus Christi Heart Project, 1988-1992","volume":"95","author":"Goff","year":"1997","journal-title":"Circulation"},{"key":"10.4065\/81.9.1177_bib6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/aje\/kwg249","article-title":"All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study: evidence against the \u201cHispanic paradox\u201d","volume":"158","author":"Hunt","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.4065\/81.9.1177_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0735-1097(97)00278-7","article-title":"Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986 to 1994)","volume":"30","author":"Liao","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/81.9.1177_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.CIR.0000158136.76824.04","article-title":"State of disparities in cardiovascular health in the United States","volume":"111","author":"Mensah","year":"2005","journal-title":"Circulation"},{"key":"10.4065\/81.9.1177_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.annepidem.2003.12.001","article-title":"Coronary heart disease mortality for six ethnic groups in California, 1990-2000","volume":"14","author":"Palaniappan","year":"2004","journal-title":"Ann Epidemiol"},{"key":"10.4065\/81.9.1177_bib10","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1006\/pmed.1998.0464","article-title":"Do Mexican Americans really have low rates of cardiovascular disease?","volume":"29","author":"Stern","year":"1999","journal-title":"Prev Med"},{"key":"10.4065\/81.9.1177_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ahj.2003.12.011","article-title":"Coronary heart disease and lipid-modifying treatment in African American patients","volume":"147","author":"Ferdinand","year":"2004","journal-title":"Am Heart J"},{"key":"10.4065\/81.9.1177_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"10.4065\/81.9.1177_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/000331979704800401","article-title":"Racial differences in risk factors for atherosclerosis: the ARIC Study","volume":"48","author":"Hutchinson","year":"1997","journal-title":"Angiology"},{"key":"10.4065\/81.9.1177_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1532-5415.2001.49030.x","article-title":"Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994: Third National Health and Nutrition Examination Survey","volume":"49","author":"Sundquist","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.4065\/81.9.1177_bib15","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1001\/jama.283.19.2579","article-title":"Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care","volume":"283","author":"Fiscella","year":"2000","journal-title":"JAMA"},{"key":"10.4065\/81.9.1177_bib16","author":"Kaiser Family Foundation"},{"key":"10.4065\/81.9.1177_bib17","first-page":"117","article-title":"Disparities in screening for and awareness of high blood cholesterol: United States, 1999-2002","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.4065\/81.9.1177_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2261-4-15","article-title":"Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study","volume":"4","author":"Massing","year":"2004","journal-title":"BMC Cardiovasc Disord"},{"key":"10.4065\/81.9.1177_bib19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archinte.162.8.929","article-title":"Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey","volume":"162","author":"Nelson","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1177_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.1995.00430070027003","article-title":"Population awareness and control of hypertension and hypercholesterolemia","volume":"155","author":"Nieto","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1177_bib21","first-page":"11","article-title":"Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients","volume":"15","author":"Hendrix","year":"2005","journal-title":"Ethn Dis"},{"key":"10.4065\/81.9.1177_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1177_bib23","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006; 354:778]","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/81.9.1177_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.4065\/81.9.1177_bib25","first-page":"366","article-title":"A review of clinical trials comparing HMG-CoA reductase inhibitors","volume":"16","author":"Illingworth","year":"1994","journal-title":"Clin Ther"},{"key":"10.4065\/81.9.1177_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/81.9.1177_bib27","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.4065\/81.9.1177_bib28","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/archinte.1995.00430170096012","article-title":"Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia","volume":"155","author":"Jacobson","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1177_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly: results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study","volume":"154","author":"LaRosa","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1177_bib30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0002-9149(96)00330-X","article-title":"Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia","volume":"78","author":"Prisant","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1177_bib31","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.4065\/81.9.1177_bib32","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/01.CIR.0000135583.40730.21","article-title":"Perspective on selected issues in cardiovascular disease research with a focus on black Americans","volume":"110","author":"Albert","year":"2004","journal-title":"Circulation"},{"key":"10.4065\/81.9.1177_bib33","first-page":"334","article-title":"Treating hyperlipidemia in African Americans","volume":"10","author":"Prisant","year":"2000","journal-title":"Ethn Dis"},{"issue":"suppl","key":"10.4065\/81.9.1177_bib34","first-page":"S42","article-title":"Cardiovascular disease in African Americans: closing the knowledge, treatment, and outcome gap","volume":"5","author":"Watson","year":"2004","journal-title":"Rev Cardiovasc Med"},{"issue":"suppl","key":"10.4065\/81.9.1177_bib35","first-page":"S14","article-title":"Pathobiology of atherosclerosis: are there racial and ethnic differences?","volume":"5","author":"Watson","year":"2004","journal-title":"Rev Cardiovasc Med"},{"key":"10.4065\/81.9.1177_bib36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia [published correction appears in Am J Cardiol. 2003;91:1399]","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1177_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"key":"10.4065\/81.9.1177_bib38","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.4065\/81.9.1177_bib39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1177_bib40","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/81.9.1177_bib41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1177_bib42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.9.1177_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9149(03)00474-0","article-title":"Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events","volume":"92","author":"Foley","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1177_bib44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.9.1177_bib45","first-page":"1541","article-title":"Cardiovascular risk profiling in blacks: don't forget the lipids","volume":"58","author":"Kountz","year":"1998","journal-title":"Am Fam Physician"},{"key":"10.4065\/81.9.1177_bib46","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jama.1997.03540400031027","article-title":"Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease: the Heart and Estrogen\/Progestin Replacement Study (HERS)","volume":"277","author":"Schrott","year":"1997","journal-title":"JAMA"},{"key":"10.4065\/81.9.1177_bib47","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"10.4065\/81.9.1177_bib48","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.amjcard.2004.01.067","article-title":"C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study)","volume":"93","author":"Albert","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.9.1177_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2005.04.051","article-title":"Race and gender differences in C-reactive protein levels","volume":"46","author":"Khera","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/81.9.1177_bib50","first-page":"2351","article-title":"The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration","volume":"27","author":"Wener","year":"2000","journal-title":"J Rheumatol"},{"key":"10.4065\/81.9.1177_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9343(86)90303-7","article-title":"Racial differences in serum creatine kinase levels","volume":"81","author":"Black","year":"1986","journal-title":"Am J Med"},{"key":"10.4065\/81.9.1177_bib52","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ajcp\/79.5.582","article-title":"Heterogeneity of serum creatine kinase activity among racial and gender groups of the population","volume":"79","author":"Wong","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"10.4065\/81.9.1177_bib53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T14:04:05Z","timestamp":1558101845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611612299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0025619611612299"],"URL":"https:\/\/doi.org\/10.4065\/81.9.1177","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}